Boost.ai Appoints Jerry Haywood as Chief Executive Officer
25.11.2022 11:01:00 EET | Business Wire | Press release
Boost.ai, a Nordic Capital-backed global leader in conversational AI for enterprises, today announced that Jerry Haywood is joining the company’s executive team as Chief Executive Officer effective December 1, 2022. Haywood brings 20 years of enterprise technology experience with him and has held various sales and senior leadership positions at IBM, Cisco, and Salesforce. He joins Boost.ai from LivePerson, a global technology company that develops conversational commerce and AI software. Haywood will succeed founder and current CEO Lars Ropeid Selsås, who desires to devote more time to product development and innovation.
Selsås, who was actively involved in the selection process, alongside Co-Founder and Chief Commercial Officer Henry Vaage Iversen, and Chief Operating Officer Camilla Gjetvik, stated: “During this time of accelerated digital customer experience transformation, Boost.ai has never been better positioned to become a global category leader in conversational AI. This change in leadership is a natural step in the next growth phase for Boost.ai. Jerry is a strong and experienced visionary leader who can build on the solid foundation created over the last six years, and we are thrilled to have him join us. While it is his outstanding track record that made him a natural candidate for this key leadership role, it was his personality and people-oriented leadership style that impressed us most. He is approachable, humble, and full of energy. A natural leader who can create results while making it a fun ride.”
Vaage Iversen added: “I am very happy that Jerry has agreed to join the Boost.ai team as CEO and I'm glad that we are able to fulfil Lars’ desire to focus even more on what he is most passionate about - the technology needed to fundamentally disrupt the conversational AI category and to continue to provide the best automated customer interaction solution available on the market.”
For the last three years, Haywood has held the role of SVP EMEA at LivePerson, where he led the strategic repositioning of the company in Europe, achieving impressive growth. Prior to LivePerson, Haywood spent eight years at Salesforce, where he headed up Service Cloud first in the UK, and then for the rest of Europe, achieving an increase of over 30% in revenue and bookings year after year.
Haywood said: “I am really excited and honoured to join the Boost.ai team, at a time where the owners and leadership want to accelerate growth while positioning the company as a global category leader in the conversational AI space. Boost.ai is already very familiar to me. I have followed their amazing journey closely and I am convinced that the scale up has what it needs to go all the way. Boost.ai has the best technology available and an amazing team with some of the brightest minds in the industry. I want to thank the founders, the Board of Directors and Nordic Capital for their trust. I can't wait to meet the team across the globe and get started.”
Haywood will balance his time between Stavanger, Norway, where Boost.ai is headquartered, and London, UK, one of Boost.ai’s key markets, where he lives with his wife and three children.
About Boost.ai
Boost.ai specializes in enterprise-grade conversational artificial intelligence (AI). Inventor of the world’s most scalable conversational AI platform, Boost.ai empowers enterprises to automate customer service and internal support channels, enhance human efficiency, and drive revenue with proprietary self-learning AI and a no-code solution that’s quick to deploy, easy to learn and highly scalable. Learn more at boost.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221125005046/en/
Contact information
Press contact
Thoms Müllertz, Chief Marketing Officer
Tel::+45 20989479
E-mail: thomas.mullertz@boost.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom